Other targeted therapies are available across solid tumors, including CCA, and include: NTRK inhibitors (entrectinib and larotrectinib); a BRAF/MEK inhibitor combination (dabrafenib and trametinib); pembrolizumab (for high ≥ 10 mutations/mb tumor mutational burden or mismatch repair defect cancers); and RET inhibitors (selpercatinib). This evidence concerns the gene MAP2K7 and cancer.